International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

A. Younes; P. Hilden; B. Coiffier; A. Hagenbeek; G. Salles; W. Wilson; J. F. Seymour; K. Kelly; J. Gribben; M. Pfreunschuh; F. Morschhauser; H. Schoder; A. D. Zelenetz; J. Rademaker; R. Advani; N. Valente; C. Fortpied; T. E. Witzig; L. H. Sehn; A. Engert; R. I. Fisher; P. L. Zinzani; M. Federico; M. Hutchings; C. Bollard; M. Trneny; Y. A. Elsayed; K. Tobinai; J. S. Abramson; N. Fowler; A. Goy; M. Smith; S. Ansell; J. Kuruvilla; M. Dreyling; C. Thieblemont; R. F. Little; I. Aurer; M. H.J. Van Oers; K. Takeshita; A. Gopal; S. Rule; S. de Vos; I. Kloos; M. S. Kaminski; M. Meignan; L. H. Schwartz; J. P. Leonard; S. J. Schuster; V. E. Seshan

doi:10.1093/annonc/mdx097

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

A. Younes, P. Hilden, B. Coiffier, A. Hagenbeek, G. Salles, W. Wilson, J. F. Seymour, K. Kelly, J. Gribben, M. Pfreunschuh, F. Morschhauser, H. Schoder, A. D. Zelenetz, J. Rademaker, R. Advani, N. Valente, C. Fortpied, T. E. Witzig, L. H. Sehn, A. EngertR. I. Fisher, P. L. Zinzani, M. Federico, M. Hutchings, C. Bollard, M. Trneny, Y. A. Elsayed, K. Tobinai, J. S. Abramson, N. Fowler, A. Goy, M. Smith, S. Ansell, J. Kuruvilla, M. Dreyling, C. Thieblemont, R. F. Little, I. Aurer, M. H.J. Van Oers, K. Takeshita, A. Gopal, S. Rule, S. de Vos, I. Kloos, M. S. Kaminski, M. Meignan, L. H. Schwartz, J. P. Leonard, S. J. Schuster, V. E. Seshan

Hematology

Research output: Contribution to journal › Review article › peer-review

103 Scopus citations

Abstract

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new “basket” clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [¹⁸F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Original language	English (US)
Pages (from-to)	1436-1447
Number of pages	12
Journal	Annals of Oncology
Volume	28
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdx097
State	Published - Jul 2017

Keywords

FDG-PET
immunotherapy
lymphoma
response criteria
targeted therapy
waterfall plots

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdx097

Cite this

Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., ... Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology, 28(7), 1436-1447. https://doi.org/10.1093/annonc/mdx097

Younes, A, Hilden, P, Coiffier, B, Hagenbeek, A, Salles, G, Wilson, W, Seymour, JF, Kelly, K, Gribben, J, Pfreunschuh, M, Morschhauser, F, Schoder, H, Zelenetz, AD, Rademaker, J, Advani, R, Valente, N, Fortpied, C, Witzig, TE, Sehn, LH, Engert, A, Fisher, RI, Zinzani, PL, Federico, M, Hutchings, M, Bollard, C, Trneny, M, Elsayed, YA, Tobinai, K, Abramson, JS, Fowler, N, Goy, A, Smith, M, Ansell, S, Kuruvilla, J, Dreyling, M, Thieblemont, C, Little, RF, Aurer, I, Van Oers, MHJ, Takeshita, K, Gopal, A, Rule, S, de Vos, S, Kloos, I, Kaminski, MS, Meignan, M, Schwartz, LH, Leonard, JP, Schuster, SJ & Seshan, VE 2017, 'International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)', Annals of Oncology, vol. 28, no. 7, pp. 1436-1447. https://doi.org/10.1093/annonc/mdx097

@article{ce97a143201d4a0d974e29d8642c9b1d,

title = "International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)",

abstract = "In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new “basket” clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.",

keywords = "FDG-PET, immunotherapy, lymphoma, response criteria, targeted therapy, waterfall plots",

author = "A. Younes and P. Hilden and B. Coiffier and A. Hagenbeek and G. Salles and W. Wilson and Seymour, {J. F.} and K. Kelly and J. Gribben and M. Pfreunschuh and F. Morschhauser and H. Schoder and Zelenetz, {A. D.} and J. Rademaker and R. Advani and N. Valente and C. Fortpied and Witzig, {T. E.} and Sehn, {L. H.} and A. Engert and Fisher, {R. I.} and Zinzani, {P. L.} and M. Federico and M. Hutchings and C. Bollard and M. Trneny and Elsayed, {Y. A.} and K. Tobinai and Abramson, {J. S.} and N. Fowler and A. Goy and M. Smith and S. Ansell and J. Kuruvilla and M. Dreyling and C. Thieblemont and Little, {R. F.} and I. Aurer and {Van Oers}, {M. H.J.} and K. Takeshita and A. Gopal and S. Rule and {de Vos}, S. and I. Kloos and Kaminski, {M. S.} and M. Meignan and Schwartz, {L. H.} and Leonard, {J. P.} and Schuster, {S. J.} and Seshan, {V. E.}",

note = "Publisher Copyright: {\textcopyright} 2017 THE AUTHORS",

year = "2017",

month = jul,

doi = "10.1093/annonc/mdx097",

language = "English (US)",

volume = "28",

pages = "1436--1447",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

AU - Younes, A.

AU - Hilden, P.

AU - Coiffier, B.

AU - Hagenbeek, A.

AU - Salles, G.

AU - Wilson, W.

AU - Seymour, J. F.

AU - Kelly, K.

AU - Gribben, J.

AU - Pfreunschuh, M.

AU - Morschhauser, F.

AU - Schoder, H.

AU - Zelenetz, A. D.

AU - Rademaker, J.

AU - Advani, R.

AU - Valente, N.

AU - Fortpied, C.

AU - Witzig, T. E.

AU - Sehn, L. H.

AU - Engert, A.

AU - Fisher, R. I.

AU - Zinzani, P. L.

AU - Federico, M.

AU - Hutchings, M.

AU - Bollard, C.

AU - Trneny, M.

AU - Elsayed, Y. A.

AU - Tobinai, K.

AU - Abramson, J. S.

AU - Fowler, N.

AU - Goy, A.

AU - Smith, M.

AU - Ansell, S.

AU - Kuruvilla, J.

AU - Dreyling, M.

AU - Thieblemont, C.

AU - Little, R. F.

AU - Aurer, I.

AU - Van Oers, M. H.J.

AU - Takeshita, K.

AU - Gopal, A.

AU - Rule, S.

AU - de Vos, S.

AU - Kloos, I.

AU - Kaminski, M. S.

AU - Meignan, M.

AU - Schwartz, L. H.

AU - Leonard, J. P.

AU - Schuster, S. J.

AU - Seshan, V. E.

PY - 2017/7

Y1 - 2017/7

N2 - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new “basket” clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

AB - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new “basket” clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

KW - FDG-PET

KW - immunotherapy

KW - lymphoma

KW - response criteria

KW - targeted therapy

KW - waterfall plots

UR - http://www.scopus.com/inward/record.url?scp=85028014921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028014921&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx097

DO - 10.1093/annonc/mdx097

M3 - Review article

C2 - 28379322

AN - SCOPUS:85028014921

SN - 0923-7534

VL - 28

SP - 1436

EP - 1447

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this